SGS at World Vaccine Congress: Can Human Challenge Trials Show Upper-Respiratory Pathogen Immunity?
SGS, a leading life sciences, clinical and bioanalytical contract solutions provider, has announced that Adrian Wildfire, Project Director, Infectious Diseases and Human Challenge Unit, will be presenting at the upcoming World Vaccine Congress. The congress will be held at the EPIC SANA Lisboa Hotel, Lisbon, Portugal, from October 29 to 31, 2018.
On Tuesday, October 30, 3:05p.m., Adrian Wildfire will present “Inverse seroconversion following Live Influenza Virus challenge.” The presentation will feature a case study where, following the inoculation of 36 healthy, adult volunteers with A/Belgium/4217/2015 [H3N2], data from a series of plots were made for mean and median seroconversion as measured by microneutralization. These showed that patterns of seroconversion were inversely related to inoculum titer. Animal studies into routes of inoculation for influenza appear to suggest profound changes in Th1 and Th2 responses dependent on the site of challenge and also the role of specific T-cell populations in the control of airways disease. Adrian Wildfire will discuss whether this, and other similar findings, could lead to the use of human challenge models to evidence the roles of T and B cells in immunity to upper-respiratory pathogens.
Adrian Wildfire, along with Bruno Speder, Head of Clinical Regulatory Affairs & Consultancy at SGS Clinical Research, will also chair a roundtable at the event at 11:40a.m. on Monday, October 29, entitled “The Regulators’ Relationship with Challenge Studies, Yesterday, Today and Tomorrow.”
Adrian Wildfire has over 30 years of experience in communicable diseases. He has trained and worked within the fields of bacteriology, virology, parasitology and mycology, obtaining his Fellowship in Medical Microbiology in 1990 and a Masters in Parasitology in 1998. He is the author of numerous papers and has been employed by infectious disease key opinion leaders in tuberculosis, HIV, and influenza/upper respiratory tract infections at various hospitals, academic institutions and contract research organizations. These include the Royal Postgraduate Medical School (Imperial College), the St. Stephen’s Centre (Chelsea and Westminster Hospital) and hVivo (formerly Retroscreen).
Bruno Speder is a pharmaceutical engineer and has over 10 years’ experience in drug development. He is a member of the advisory board of several biotech companies and guest lecturer on clinical research in the honours Program of the Ghent University.
SGS is a leading life sciences CRO providing clinical research, bioanalytical, biologics characterization, biosafety and quality control testing. Delivering solutions in Europe and the US, SGS offers clinical trial (Phase I to IV) services encompassing clinical project management and monitoring, biometrics, PK/PD modeling and simulation, and regulatory and medical affairs consultancy. SGS has its own clinical unit in Belgium and two Phase I patient units in Belgium and Hungary.
SGS has a wealth of expertise in first in human (FIH) studies, viral challenge testing, biosimilars and complex PK/PD studies with a focus on infectious diseases, vaccines and respiratory therapeutics.
For more information, visit the World Vaccine Congress website.
To arrange a meeting with Adrian Wildfire and Bruno Speder at the conference, please contact Richard Kerns at NEPR.
For further information, please contact:
SGS is the world’s leading inspection, verification, testing and certification company. SGS is recognized as the global benchmark for quality and integrity. With more than 95,000 employees, SGS operates a network of over 2,400 offices and laboratories around the world.